Skip to main content
Publications
Horn L, Bauml J, Forde PM, Davis KL , Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer . Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C , Hollis K , Sweeney C , Price M , Wolowacz S , Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS) . Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007
Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M , Chirila C , Hollis K , Sweeney C , Wolowacz S , Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study . Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.
Arana A , Margulis AV , McQuay LJ, Ziemiecki R , Bartsch JL , Rothman KJ , Franks B, D Silva M, Appenteng K, Varas-Lorenzo C, Perez-Gutthann S . Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a cohort study in the UK . Pharmacotherapy. 2018 Jun;38(6):628-37. doi: 10.1002/phar.2121.
Kaye JA, Castellsague J, Bui CL , Calingaert B , McQuay LJ, Riera-Guardia N , Saltus CW , Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ , Wallander M-A, Perez-Gutthann S . Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study . Pharmacotherapy. 2014 Apr;34(4):336-49. doi: 10.1002/phar.1367